LDN-193189, CAS 1062368-24-4

Formulation: A crystalline solid

Formal Name: 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline

Purity: ≥95%

Formula Markup: C25H22N6

Formula Weight: 406,5

Shelf life (days): 1460

CAS Number: 1062368-24-4

Notes: Normal development and tissue repair are controlled in part by SMADs, a family of intracellular proteins that are activated by signaling via serine/threonine kinase receptors of the TGF-β superfamily.{9612} LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-like kinases (ALKs), with an IC50 value of 4.9 nM.{23386} In in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively).{23387} LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.{23384,23385}

• Artikelnummer: CAY11802-25
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 11802-25
• Green Labware: Nein
• Verpackungseinheit: 25 mg
• Mengeneinheit: STK